Sanofi completes the acquisition of Vigil Neuroscience, Inc. Paris, August 6, 2025. Sanofi announces the completion of its acquisition of Vigil Neuroscience, Inc. (“Vigil”). This acquisition ...

Vigil Neuroscience, Inc. has announced its plans to report data from its Phase 1 clinical trial of VG-3927, a TREM2 agonist for Alzheimer’s disease, in the first quarter of 2025, and expects to ...

--Vigil Neuroscience, Inc., a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases and Sanofi, today announced that ...

WATERTOWN, Mass., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the ...

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the ...

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the ...

Net Loss: Net loss from operations for the first quarter ended March 31, 2025 were $22.4 million, compared to $19.9 million for the same period in 2024. About Vigil Neuroscience ...

Net Loss: Loss from operations for the third quarter ended September 30, 2023, were $20.5 million, compared to $17.5 million for the same period in 2022. About Vigil Neuroscience ...

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment ...